Trade Summary

1 month ago, Akkaraju Srinivas, serving as Dir, 10% owner at Kalaris Therapeutics, Inc. (KLRS), purchased 244,300 shares at $4.83 per share, for a total transaction value of $1,179,969.00. Following this transaction, Akkaraju Srinivas now holds 12,915,520 shares of KLRS.

This purchase represents a 2.00% increase in Akkaraju Srinivas's stake in the company. This is considered a medium-conviction trade.

The trade was executed on Wednesday, May 20, 2026 and publicly disclosed via SEC Form 4 filing on Friday, May 22, 2026 at 7:47 PM ET, 2 days after the trade was made.

Kalaris Therapeutics, Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider buying activity in this sector can provide valuable signals about industry trends and company-specific developments.